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Systemic lupus erythematosus (SLE), a chronic multisystem autoimmune disease with a broad range of clinical manifestations,
is associated with accelerated atherosclerosis (AT) and increased risk of cardiovascular complications. Relevant factors directly
inﬂuencing the development of AT comprise immune complex generation, complement activation, and changes in the production
and activity of a complex network of cytokines, including type I and II interferons, B lymphocyte stimulator (BLyS), TNFα,I L -
6, IL-17 and migration macrophage inhibitor (MIF). Autoantibodies, also responsible for cytokine expression and activation,
play a supplementary key role in the development of AT. Genomic and proteomic studies have contributed to the discovery of
genes and proteins involved in AT, including some that may be suitable to be used as biomarkers. All that data has allowed the
developmentofnewdrugs,mostofthemevaluatedinclinicaltrials:inhibitorsofIFNandTNFα,Bcelldirectedtherapies,synthetic
oligodeoxynucleotides, intravenous immunoglobulin, or statins. The focus of the present paper is to summarize recent evidence
showing the role of cytokines in the development of AT in SLE and the rationale, and safety concerns, in the use of combined
therapy to prevent AT and cardiovascular disease.
1.Introduction
SLE is a chronic multisystem autoimmune disease with a
broad range of clinical manifestations, including photosensi-
tive skin rashes, discoid lesions, arthritis/arthralgia, nephri-
tis, cardiac and pulmonary disease, and CNS disorders. The
disease pathogenesis is attributed to circulating antinuclear
autoantibodies against a variety of nuclear antigens (includ-
ing dsDNA, the ribonucleoprotein (RNP) complex Ro, the
RNA-binding protein LA, RNPs, the RNA molecule/protein
complex Sm, the C1 complement component subunit C1q,
and phospholipids) and the dysfunction of T and B lympho-
cytes and dendritic cells [1].
Although the pathogenesis is believed to lie in the
dysregulation of the immune system, the involvement of
various organ systems often leads to secondary morbidities
resulting from renal failure, hypertension, or CNS disorders,
andmorerecentlyitisbecomingincreasinglyclearthataccel-
erated atherosclerosis associated with SLE may contribute to
premature mortality [2].
Atherosclerosis (AT) is a chronic inﬂammatory disease
of the arteries associated with various risk factors that pro-
mote lipid abnormalities (i.e., dyslipidemia), development
and progression of atherosclerotic lesions, plaque rupture,
and vascular thrombosis [3]. AT is enhanced in autoim-
mune diseases; noninvasive investigations show increases in
intima-media thickness, carotid plaque, and coronary artery
calciﬁcations in patients with antiphospholipid syndrome
(APS), systemic lupus erythematosus (SLE), and rheumatoid
arthritis (RA) compared to controls [4]. The reason for
this accelerated process is still debatable and, although
traditional risk factors (such as hyperlipidemia, smoking,
obesity, hypertension, diabetes mellitus, postmenopausal
status, and sedentary lifestyle) are more prevalent in those2 Journal of Biomedicine and Biotechnology
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Figure 1: Mechanisms leading to atherogenesis and Cardiovascular disease in SLE patients. ECs: endothelial cells; VSMCs: vascular smooth
muscle cells; TNF: tumour necrosis factor; ILs: interleukins; IFN: interferon; BLyS: B lymphocyte stimulator.
patientsthaningeneralpopulation, theydonotseemtofully
explain that enhanced risk [5].
Experimental studies and human observations suggest
that innate and adaptive immune responses participate in
the pathogenesis of both AT and autoimmune diseases.
Actually, some autoantibodies, including antioxidized low
density lipoproteins (antioxLDL), antiβ-2-Glycoprotein 1
(antiβ2GPI), antiHeat shock proteins 60/65 (antiHSP60/65),
and antioxLDL/β2GPI, have been shown to be associated
to the pathogenesis of AT [6, 7]. However, their role in
accelerated AT in APS and SLE patients is still controversial.
Identiﬁed additional factors for AT in patients with
SLE include chronic inﬂammation and chronic exposure
to steroid therapy. These factors can directly inﬂuence the
development of AT through a variety of mechanisms such
as immune complex generation, complement activation,
alteration of the oxidant-antioxidant balance locally within
the vessel wall, and changes in the production and activity of
a complex network of cytokines [8–10]( Figure 1).
Characterization of the molecular and cellular basis of
signalling abnormalities within the immune system that lead
to auto reactivity and inﬂammation and their relationship to
earlyatherosclerosisandcardiovasculardisease(CVD)devel-
opment remain critical for understanding the pathogenesis
of SLE.
2.Cytokines as Immune Mediators Involved in
Atherosclerosis and CVD Development
The vascular inﬂammatory response involves complex inter-
action between inﬂammatory cells (neutrophils, lympho-
cytes, monocytes, and macrophages), endothelial cells (ECs),
vascular smooth muscle cells (VSMCs), and extracellular
matrix (ECM). Vascular injury is associated with increased
expression of adhesion molecules by ECs and recruitment
of inﬂammatory cells, growth factors, and cytokines, with
consequent eﬀects on ECs, VSMCs, and ECM. Cytokines
include tumour necrosis factor, interleukins, lymphokines,
monokines, interferons, colony stimulating factors, and
transforming growth factors. Cytokines are produced by
macrophages, T-cells and monocytes, as well as platelets,
E C sa n dV S M C s[ 11]. Depending on their cellular source,
cytokines are classiﬁed into type 1 cytokines, produced by
Th1 T-helper cells, that include IL-2, IL-12, IFN-γ,a n d
TNF-β; and type 2 cytokines, produced by Th2 T-helper
cells that include IL-4, -5, -6, -10, and -13. Th1 cytokines
tend to drive cellular inﬂammatory responses including
macrophage activation. The Th2 cytokines play a role in
distinct inﬂammatory processes, and may inhibit certain
forms of autoimmunity [12]. Circulating cytokines interact
with speciﬁc receptors on various cell types and activateJournal of Biomedicine and Biotechnology 3
signalling pathways leading to an inﬂammatory response
involving cell adhesion, permeability, and apoptosis [11].
Cytokines are master regulators of the innate and
adaptive immune response and, unsurprisingly, are known
to regulate and, essentially, coordinate many stages of
atherosclerosis [13, 14]. Many cytokines, such as Interleukin
(IL)-1, IL-6, IL-10, interferon IFNγ,a n dT N F α are expressed
highly in atherosclerotic regions and exhibit pro- and
antiatherogenic actions [13–15].
Innate cytokines such as IL-1 or TNF may acti-
vate endothelial cells (ECs), vascular smooth muscle cells
(VSMCs), monocytes/macrophages, lymphocytes (T, B,
NK), dendritic cells, and mast cells. These vascular cells can
actively contribute to the inﬂammatory cytokine-dependent
response in the vessel wall by production of cytokines
or eliciting responses to cytokines, or can be involved
in cytokine-mediated interaction with invading cells such
as monocytes, T-cells, or mast cells. Activation of these
pathways results in accumulation of cells and increased
LDL- and ECM-deposition which may facilitate subsequent
invasions [11].
Numerous abnormalities of the cytokine network have
been described in patients with SLE as well as in murine
lupus models. Some of them were shown to play a pivotal
physiopathological role in certain T-cell, B-cell or antigen
presenting cell dysfunctions characteristic of the disease,
while others are more likely to be innocent bystanders [16].
3. Cytokines Involvedin the Pathogenesis of
Atherosclerosis in SLE
Several cytokines with relevance to CVD has been proven to
be related to the pathogenesis of AT in SLE. In the following
paragraphs we highlight some of the most likely signiﬁcantly
involved.
Plasmacytoid dendritic cells (pDC) activated by immune
complexes containing nucleic acids secrete type I IFN (IFNα
and IFNβ) in SLE. Type I IFN causes diﬀerentiation of
monocytes to myeloid-derived dendritic cell (mDC) and
activation of autoreactive T and B cells. Patients with
SLE have an increased expression of type I IFN-regulated
g e n e sb e c a u s eo fac o n t i n u o u sp r o d u c t i o no fI F N α.R e c e n t
r e p o r t sh a v ed e m o n s t r a t e dt h a te l e v a t e dl e v e l so ft y p eII F N s
(cytokines with potent antiproliferative and antiangiogenic
eﬀects, and associated with active SLE disease, and posi-
tivity for some autoantibodies) could lead to endothelial
dysfunction through the promotion of a reduction in the
number of endothelial progenitor cells (EPCs, responsible
for the neovascularization in sites of endothelial injury),
thus contributing to the increased CV risk observed in SLE
[17]. In that way, a recent study by Denny and coworkers
[18] showed that SLE patients displayed not only signiﬁcant
decreases in the number of circulating EPCs, but also
signiﬁcant impairments in the capacity of EPCs/CACs—
circulating angiogenic cells to diﬀerentiate into mature ECs
and synthesize adequate levels of proangiogenic molecules
vascular endothelial growth factor (VEGF) and hepatic
growth factor (HGF). Moreover, that study showed that
lupus EPCs/CACs had increased IFNα expression. By con-
tributing to endothelial disjunction/damage and induc-
ing proinﬂammatory responses within the atherosclerotic
plaque, IFNs could promote AT in patients with SLE.
T h er o l eo ft h et y p eI Ii n t e r f e r o n( I F N γ)—whose
expression is signiﬁcantly increased in peripheral blood
mononuclear cells (PBMCs) of SLE patients [19]—in the
progression of atherosclerosis has been well debated due to
evidence conveying both pro- and antiatherogenic actions of
the cytokine. Since IFNγ, known to be a proinﬂammatory
cytokine, can also display antiinﬂammatory properties [20],
it is likely that it acts in both ways in AT. These conﬂicting
actions may well be gene-speciﬁc and it is known that
approximatelyaquarterofallgeneswithinthetranscriptome
of the macrophage, a key immune cell involved in AT, is
sensitive to IFNγ [21]. IFNγ has been shown to inﬂuence
many features of atherosclerosis such as foam cell formation,
the adaptive Th1-speciﬁc immune response and plaque
development [22]. In the global context of AT, it is possible
thatitsproatherogenicactionsout-weightitsantiatherogenic
ones. Nevertheless, the precise role of this type of IFN in the
development of AT in SLE patients remains to be analyzed.
IFNs are often profoundly dysregulated in SLE, and both
IFNα and IFNγ have been shown to induce B lymphocyte
stimulator (BLyS) expression. BLyS (also known as the B
cell-activating factor belonging to the TNF family, or BAFF
[23]) was identiﬁed as a novel TNF family ligand, and has
proven to be a key factor in the selection and survival of B
cells [23–26]. The BLyS protein is expressed by a wide variety
of cell types, including monocytes, activated neutrophils, T
cells and DCs [27–29]. Although standing levels of BLyS are
constitutively generated, its expression and secretion can be
potentiated by inﬂammatory cytokines, such as IL-2, TNFα,
and IFNγ [28–31]. BLyS levels aﬀect survival signals and
selective apoptosis of autoantibody-producing B cells. High
levels of BLyS may relax B cell selection and contribute
to autoantibody production, exacerbating the SLE disease
state. It has been hypothesised a potential cooperative action
of BLyS and IFNs in the aetiology of SLE. Since BLyS is
not known to have direct or immediate proinﬂammatory
activities, changes in serum BLyS levels are unlikely to trigger
acute inﬂammatory reactions and disease manifestations.
However, it is possible than an increase in disease activity
may lag behind increases in circulating BLyS levels due to
indirector“delayed”eﬀectsofBLySinthesystemicimmune-
inﬂammatory reactions of SLE. Nevertheless, the possible
association between the overexpression of BLyS and the
development and/or progression or AT or CVD in SLE
patients remains elusive.
TNFα is both a proinﬂammatory and an immunoregu-
latory cytokine. TNFα has diﬀerential eﬀects on monocytes,
on B cells, on T cells, and on dendritic cells, as well as on
the process of programmed cell death. TNFα is a growth
factor for B lymphocytes, and B lymphocytes are able to
produce signiﬁcant amounts of TNFα in an autocrine loop
[32].TNFαmayalsoexertasigniﬁcantinﬂuenceonBcellsby
its capacity to induce IL-6 [33]. Moreover, TNFα stimulation
leads to increased production of IFNγ, a cytokine with a
clear-cut pathological role in SLE, as previously described4 Journal of Biomedicine and Biotechnology
[34]. TNFα also constitutes an activating cytokine and a
maturation factor of dendritic cells, which are essential
in immune regulation and have also been implicated in
autoimmunity in general, and in SLE in particular [35].
In addition, the elevated circulating levels of TNFα found
in SLE patients have been found to be associated with
high triglyceride and low HDL levels [36]. Moreover, in a
recent study by Rho and coworkers [37] it was established
a signiﬁcant association between TNFα expression levels and
the severity of coronary calcium scores in SLE patients. Yet,
that data should be further conﬁrmed in a new cohort of
patients, as a previous study by Roman et al. [38] found no
association among TNFα, IL6, or CD40L and the presence of
carotid plaque in SLE.
Nevertheless, because of its wide involvement in the
activity of monocytes, dendritic cells, and lymphocytes as
well as in the expression of other inﬂammatory cytokines
involved in AT development, TNFα may be considered
a major factor in SLE-related CVD, acting both by
contributing to hypertriglyceridaemia and by promoting
atherosclerosis-related inﬂammation.
Interleukin-6 (IL-6) is a pleiotropic cytokine with a wide
range of biological activities that plays an important role
in immune regulation and inﬂammation. Furthermore an
association between IL-6 and lupus was demonstrated in
murine models of SLE and blocking IL-6 improved lupus
in all models tested [39]. IL-6 is one of the most important
B cell stimulating factors that induces the diﬀerentiation of
T cells into eﬀectors cells. Immunoglobulin and antiDNA
antibody production in vitro by B cells from lupus patients
hasbeendemonstratedtobepromotedbyIL-6andinhibited
by antibodies against IL-6 or the IL-6 receptor. IL-6 is
involved in the recruitment of inﬂammatory cells and lipid
homeostasis and is associated with increased cardiovas-
cular mortality and prognosis in the general population.
Moreover, IL-6 drives c-reactive protein (CRP) production,
which itself plays multiple roles, inﬂuencing key promoters
of AT; moreover, it appears as an independent predictor
of coronary events [40]. However, the role of IL-6 in
the pathogenesis of SLE-related AT is also controversial.
Some authors found elevated IL-6 levels only in cases with
increased CRP, concluding that it is part of the acute phase
response [41]. Others defend the idea that the relationship
between IL-6 concentrations and the burden of AT in SLE
patients represents more than an epiphenomenon, and that
measurementofIL-6providessupplementaryinformationin
this cohort of SLE patients [42].
IL-17 is a pro-inﬂammatory cytokine which participates
in the defence against certain pathogens, primarily extra-
cellular bacteria and fungi [43]. IL-17 is produced by several
cell subsets including CD4+ T cells, CD8+ T cells, NK cells
and neutrophils [43]. In addition to its proinﬂammatory
capacity, IL-17 exerts its eﬀects through the recruitment
of monocytes and neutrophils by increasing the local
production of chemokines (IL-8, monocyte chemoattrac-
tant protein-1, growth-related oncogene protein-alpha) [44–
48], the facilitation of T cell inﬁltration and activation
by stimulating the expression of intercellular adhesion
molecule-1 [49] as well as the ampliﬁcation of the immune
response by inducing the production of IL-6, prostaglandin
E2, granulocyte-macrophage colony-stimulating factor and
granulocyte colony-stimulating factor [50, 51]. Additionally,
IL-17 synergizes with other cytokines, in particular with
IL-1β,T N F α,a n dI F N γ [52–55]. Th17 cells have been
implicated in the pathogenesis of autoimmune diseases
including rheumatoid arthritis [56] and multiple sclerosis
[57], and recent evidence suggested that IL-17-mediated
inﬂammation might play a role in the pathogenesis of SLE.
Also abnormally high levels of IL-17 and IL-23 have been
reported in human SLE sera [58], and more recently it has
been provided evidence that IL-17 production by T cells is
increased in SLE patients [59]. That study further described
that double negative (C4-CD8-) T cells, which are expanded
in the peripheral blood of patients with SLE [60], represent
major producers of IL-17, and that they undergo a vigorous
proliferative response following stimulation.
Averyrecentstudy[61]hasdemonstratedaconcomitant
presenceofIL-17andIFNγ inpatientsandclinicalspecimens
ofcoronaryatherosclerosis,thepresenceofIL-17/IFNγ dual-
producing T cells within coronary plaques, and a synergistic
eﬀect of IL-17 and IFNγ on elicitation of proinﬂammatory
cytokine and chemokine production by cultured human
VSMC. Thus an association of this cytokine with human
coronary AT has been already established. However, its role
in SLE-related AT remains to be evaluated.
Macrophage migration inhibitory factor (MIF) has
emerged as a potential link between SLE and atherosclerosis
development [10, 62]. Increased serum levels of MIF have
been detected in SLE patients compared with healthy control
individual. MIF is a pleiotropic cytokine with roles in several
inﬂammatory diseases. MIF induces the pro-inﬂammatory
mediators TNFα, IL-1, IL-6 and MMPs. It can activate T
cells, promote angiogenesis and induce proliferation of cells,
while inhibiting p53 expression and apoptosis of the same
cells [62, 63]. MIF can be induced by oxLDL, which is
an initiating factor in atherogenesis, and so expression of
MIF early on may enhance pro-inﬂammatory responses and
lesion progression [63].
The interaction between CD40 and CD40L is also an
integral part of the inﬂammatory pathway in the vascu-
lar system. CD40 ligation on cells of the vascular wall
promotes mononuclear cells recruitment and contributes
to thrombosis in the setting of atherosclerosis [64]. The
co-stimulatory molecule CD40 ligand (CD40L, also called
sCD154) is a member of the TNF family and participates
in B cell diﬀerentiation and proliferation [65]a sw e l la s
in antibody isotype switching [66]. The binding of CD40L
to its receptor, CD40, is thought to also be involved in
atherogenesis and atherosclerotic plaque rupture [67–69].
Some reports indicated elevated serum concentrations of
CD40L in patients with SLE compared to matched control
subjects [70, 71]. CD40L has been found to be over
expressed in T cells of patients with SLE [72], and elevated
concentrations of CD40 and CD40L have been found in
atherosclerotic plaques in SLE patients [67].
Animportantoutcomederivedfromthestudiesreported
on this area is that only for a few cytokines there is suﬃ-
cient consistent data allowing classifying them as typicallyJournal of Biomedicine and Biotechnology 5
proatherogenic (IL6, IL17,IFNγ,T N F α, BAFF, MIF, etc) or
antiatherogenic (IL-10), and that some cytokines (IFNγ,
TNFα,I L 4 ,I L - 6 )c a ne x e r tp r o -o ra n t i a t h e r o g e n i ce ﬀects
depending on the disease status. This knowledge can be used
for improved early detection, prevention and treatment of
atherosclerosis in SLE.
4. Genomics and Proteomics Biomarkers
for SLE Atherosclerosis and Cytokine
Involvement
Several genomic studies have been developed on SLE PBMCs
[73–79]( Table 1). Genomic studies have consistently given
strong support to the involvement of a dysregulation of IFN-
dependent pathways in the pathogenesis of SLE [80, 81].
Analysis of SLE-upregulated genes showed a predominance
of genes known to be upregulated in response to IFN.
In some cases, expression results obtained using DNA
microarrays were also conﬁrmed by independent methods
such as quantitative real-time reverse transcription PCR
[79, 82]. Additional changes that may be of great importance
in determining the high thrombotic risk of SLE patients
include the upregulation of other gene families such as TNF
andTNFreceptor,chemokinesandchemokinereceptors,cell
surfaceactivationantigens,FCreceptors,metalloproteinases,
and defensins [80]. Interestingly, many of the expression
changes observed in PBMCs isolated from SLE patients were
reproduced in healthy PBMCs cultured with IFNα [76].
The lack of detection of signiﬁcant IFNα transcripts in
SLE patient’s PBMCs supported that this cytokine may be
mainly produced by plasmacytoid dendritic cells located in
the patient’s tissues [76].
Recent searches for “lupus genes” through candidate
single nucleotide polymorphism (SNP) association scans,
havefurtherdemonstratedthatSLEisadiseasewithcomplex
genetic inheritance and no single causative gene [86]. These
studies have also given more proofs of the relationship
between genetic proﬁles and development of AT and CVD
in SLE patients. Among them, polymorphisms in the region
of the TNFAIP3 gene were recently linked to SLE [83].
TNFAIP3 encodes the deubiquitinating enzyme A20, and
endogenous inhibitor of the nuclear factor-kappaB (NFκB)
pathway. NFκB is a transcription factor that is activated
by TNF or IL-1/TLR signalling pathways, which induces
transcription of proinﬂammatory genes. In AT, NFκBi s
activated at sites of the arterial wall that are prone to lesion
development. SNPs in the TNFAIP3 gene region may cause
reduced expression or reduced activity of A20 [83], therefore
contributing to an uncontrolled inﬂammatory response
and autoimmunity and potentially accelerated AT in these
patients.
The proteomic analysis of plasma samples from SLE
patients has allowed an important observation in order
to understand the higher susceptibility of SLE patients to
suﬀer CV disorders. Pav´ on et al. [87] have studied by 2-DE
plasma samples from SLE patients and healthy controls of
initially unknown haptoglobin (Hp) phenotype, and tryptic
digests of the excised Hpa polypeptide chain spots were
analyzed by MALDI-TOF/MS. Selected tryptic peptides were
then sequenced by nano-(n)ESI-IT MS/MS. There were
remarkable interindividual diﬀerences in the Hp patterns
of SLE patients compared with those of healthy controls.
Thus, Hpa1F protein was only present in one of the patients
studied, whereas the Hpa2 isoform was detected in all but
oneSLEpatientsstudied,resultinginanHp2allelefr equency
signiﬁcantly higher than that in healthy controls. Hp func-
tions as an antioxidant and an essential endothelial protector
by binding to free haemoglobin, avoiding oxidative stress
[88]. Both the hemoglobin-binding and the antioxidant
capacity of Hpa1 is higher compared with that of Hpa2
[89] and Hp genotype plays a critical role in the oxidative
and inﬂammatory response to intraplaque haemorrhage
[90]. Moreover, Hp genotype modulates the balance of
inﬂammatory (Th1) and antiinﬂammatory (Th2) cytokines
produced by macrophages exposed to free haemoglobin,
which may have implications in understanding interindivid-
ualdiﬀerencesintheinﬂammatoryresponsetohaemorrhage
[91]. Moreover, large-artery elasticity index and small-artery
elasticityindexweresigniﬁcantlylowerandsystemicvascular
resistancewashigherinhomozygotesforthe2allele(Hp2-2)
compared with patients with Hp 2-1 or Hp 1-1 phenotypes
[92]. The knowledge of the Hp phenotypes and their PMF
by 2-DE and MS in SLE patients can help predicting or
preventing CV disorders and determining a more precise
prognosis and better treatment [87].
There are still scarce data in that area, and studies
performed are very heterogeneous. However, fundamental
pathobiological mechanisms in atherogenesis development,
and their association to autoimmune-mediated induction
of cytokine expression have been identiﬁed in SLE. Nev-
ertheless, genomic and proteomic areas are in continuous
development and new information on genetic factors and
gene and protein expression patterns in a near future are
warranted.
5. SLE Treatment and Its Inﬂuence on Cytokine
Expressionand Atherosclerosis Development
The pharmacological management of SLE is challenging,
owing to its unpredictable clinical course, the variable organ
system involvement and the lack of clear understanding of
disease pathogenesis.
Traditional management of SLE has included the use of
nonsteroidal antiinﬂammatory drugs, antimalarials, gluco-
corticoids, and immunosuppressive drugs such as azathio-
prine, methotrexate, cyclosporine A, cyclophosphamide, and
mycophenolate mofetil [93–95]. Although many of these
therapies have shown great eﬃcacy, they are often associated
with adverse eﬀects. The development of safer therapies for
SLEhasledtorecentemphasisontargetingselectedpathways
that can be important in the inﬂammatory response in SLE.
In this context, a better understanding of lupus pathogenesis
has led to the development of biological agents that are
directed at biomarkers including, inhibitors of cytokines
(e.g., TNFα or IL-10), B-cell directed therapies, statins, and
so forth.6 Journal of Biomedicine and Biotechnology
Table 1: Genomic markers of CVD risk and atherosclerosis in SLE. Some examples of genes from each category are given.
Genes/proteins associated with CVD and atherosclerosis Technique
utilized Change References
Gene Protein Accession
Genes diﬀerentially expressed in PBMCs from SLE patients
IFN target genes
IFIT1 Interferon-induced protein with
tetratricopeptide repeats-1 X06559 Up
G1P3 Interferon, alpha-inducible protein (IFI-6-16) U22970 Up
IFIT4 Interferon-induced protein with
tetratricopeptide repeats 4 O14879 Up
PLSCR1 Phospholipid scramblase 1 O15162 Up
G1P2 Interferon, alpha-inducible protein (IFI-15K) M21786 Up
IRF7 Interferon regulatory factor 7 Q92985 Up
THBS1 Thrombospondin 1 J04835 Up
FCGR1A Fc fragment of IgG, high-aﬃnity Ia receptor M63830 Up
USP20 Ubiquitin speciﬁc protease 20 Y17457 Down
MATK Megakaryocyte-speciﬁc tyrosine kinase S75164 Down
TNF and TNF receptor families
TNFSF10 TNF-related apoptosis inducing ligand (TRAIL) U37518 DNA
microarrays Up [73–80]
TNFRSF10C TRAIL receptor 3 O14798 Up
FAS Fas (TNF receptor superfamily, member 6) D31968 Up
Chemokines and chemokine receptors
CCR7 Chemokine (C-C motif) receptor 7 L31584 Up
IL8RB Interleukin 8 receptor, beta M99412 Up
Cell surface activation antigens
CD69 CD69 molecule Z30426 Up
Fc receptors
FCGR1A Fc-gamma receptor I A1 M63830 Up
FCGR2A Fc fragment of IgG, low aﬃnity IIa, receptor
(CD32) A21604 Up
Metalloproteinases
MMP3 Matrix metallopeptidase 3 J04732 Up
MMP9 Matrix metallopeptidase 9 D10051 Up
Defensins
DEFA3 Defensin 3, neutrophil-speciﬁc L12691 Up
Single nucleotide polymorphism (SNP) association scans
Gene Protein SNPs Eﬀect References
TNFAIP3 De-ubiquitinating enzyme A20
rs13192841
rs2230926
rs6922466
Reduced
expression
and activity
of A20
[83]
IRF5 IFN-regulatory factor 5 rs2004640 Increased risk
for SLE [84]
STAT4 Transcription factor rs7574865 Increased risk
for SLE [85]Journal of Biomedicine and Biotechnology 7
In SLE, the loss of self-tolerance leads to persistence and
activation of auto reactive B cells and T cells with the con-
secutive abnormal secretion of cytokines and production of
autoantibodies, which are thus interesting target candidates
forthedevelopmentofnovelSLEtherapies.Severalcytokines
have been identiﬁed as major targets in SLE, leading to the
development of numerous monoclonal antibodies, some of
them currently used in therapy or under clinical evaluation
[96].
A therapeutic option in patients with SLE is inhibition
of IFNα. Three general approaches could be used to target
IFNα: (1) reduce extra-cellular levels of IFNα;( 2 )r e d u c e
signalling from the IFNα receptor; (3) reduce the activity
of the mediators of IFNα activity. Each approach has been
shown to display pros and cons and implications for eﬃcacy
and safety needs to be weighed. Nevertheless, recent data
from a phase I clinical trial suggests that administration
of neutralizing monoclonal antibodies against IFNα can
ameliorate disease activity [97].
The foregoing evidence clearly implicates TNF in the
accelerated atherogenesis and other cardiovascular events
associated with autoimmune diseases such as rheumatoid
arthritis(RA)andSLE.SeveralTNFantagonistsarecurrently
licensed for the treatment of RA, including inﬂiximab,
adalimumab (a fully humanized monoclonal antibody) and
etanercept (a fusion protein of human soluble TNF receptor
and the Fc component of human IgG). All of these biologic
agents have been shown to be eﬀective in controlling disease
activity, as well as reducing systemic inﬂammation [98–100],
surrogate vascular and metabolic markers [101, 102], and
CVD events [103].
Limited studies have evaluated the eﬀect of antiTNF
therapy in SLE, and are discussed in a recent revision by
K a ri me ta l .[ 104]. The study by Aringer et al. [105]l o o k e da t
six patients with active SLE treated with inﬂiximab plus aza-
thioprine or methotrexate. Disease activity declined during
therapy despite the fact that levels of anti-dsDNA antibodies
and cardiolipin increased in four out of six patients. Four
out of six patients who had lupus nephritis improved their
proteinuria signiﬁcantly. There were associated infections
including urinary tract infection in three patients, one of
whom also had Escherichia coli septicaemia, and a prolonged
suspected viral fever in another patient. In the follow-
up study Aringer et al. [106] also showed an increase in
antibody detection to DNA, histone, chromatin and IgM
cardiolipin, despite an overall reduction in disease activity.
TNFα antagonist therapy has also been associated with a
lupus-like syndrome; most of these case reports occurred in
patients receiving either etanercept or inﬂiximab [107].
A small open trial used antiIL-10 monoclonal antibodies
in six patients with active SLE [108]. Ten patients received
intravenous IL-10 monoclonal antibody 20mg for 21 days
andwerefollowedfor6months.TheSLEDAIscoredecreased
signiﬁcantlybyday21,andwasmaintainedat6months.Skin
and joint symptoms improved in all patients. Prednisolone
dose reduced signiﬁcantly over the 6-month period.
Another approach was recently developed, based on
active immunotherapy, which consists of inducing antibod-
ies able to neutralize the interaction of the self-cytokine to its
receptor. In that way, in a model of RA, it was demonstrated
that vaccination with a biologically inactive but immuno-
genic human TNFα derivative (keyhole limped hemocyanin-
human TNFα heterocomplex), led to the production of high
titters of antibodies that neutralize human TNFα bioactivity
[109].
Other novel cytokines that might have a role, as
implicated by vascular epidemiologic and pathophysiologic
studies, could also be tested in the near future in the SLE
context, including IL17 or IL23, which are being investigated
in clinical trials for managing of RA. Despite the positive
results found in these studies with anticytokine therapies,
numerous side eﬀects have also been demonstrated. As
cytokine network dysregulation is highly complex in SLE,
further investigations are needed to evaluate whether this
strategy may be advantageous in SLE in the future.
B-cell directed therapies are promising treatments for
SLE patients that do not respond to the ﬁrst-line therapies.
Rituximab is a chimeric antiCD20 monoclonal antibody
which depletes B cells from the peripheral circulation, but
allows regeneration from stem cells. CD20 is expressed at
various stages of B-cell development from pre-B cells up to
mature B cells, but not on plasma cells and hematopoietic
stem cells. The exact mechanisms of action in autoimmune
disease is however as yet unknown. Rituximab causes lysis of
B cells mediated by complement and by Fc-receptor-bearing
cytotoxic cells, and also causes apoptosis. It has a variable
eﬀect on immunoglobulin levels with variable reduction
of autoantibody titres. It is possible that rituximab has
additional eﬀects on the immune system [110–112]. Several
groups have published uncontrolled studies of rituximab
treatment in SLE with positive results [113–119]. Adverse
events most frequently were infections and a risk of relapse
signiﬁcantly elevated.
A very recent study has investigated the changes in the
lipid proﬁle of SLE patients after B-cell depletion therapy
[120]. They reported that rituximab acted positively on
known risk factors for premature AT such as HDL choles-
terol, the total cholesterol/HDL ratio and Tissue Factor
(TF) levels. This improvement in the lipid abnormalities
coincided with decreased disease activity as measured by
the BILAG index and a fall in the antidsDNA antibody
levels. Since rituximab has not known direct eﬀects on lipid
metabolism, it seems likely that the positive eﬀects in the
lipid proﬁle of that set of patients is indirectly mediated
through a reduction in the inﬂammatory activity of the
disease. Larger prospective studies should evaluate if this
favourable eﬀect contributes to a lower incidence of CV
events.
Several studies have demonstrated increased levels of
hypomethylated CpG-containing DNA in sera from patients
with SLE, which may contribute to the initiation and/or
perpetuation of the disease. Thus, recent therapies have
been focused on the use of synthetic oligodeoxynucleotides
(ODN) capable of “neutralizing” or “inhibiting” immune
responses by inhibiting the activity elicited by this altered
DNA. Among them, phosphorothioate ODN mimic the
immunosuppressive activity of the repetitive TTAGGG
motifs present in mammalian telomeres. These TTAGGG8 Journal of Biomedicine and Biotechnology
multimers block the production of pro-inﬂammatory and
T helper type 1 cytokines elicited when immune cells are
activated by a wide variety of Toll-like receptor ligands
(TLRs), polyclonal activators, and antigens. The suppressive
activityofsuchODNhasbeenattributedtotheirinterference
with the phosphorylation of signal transducer and activator
of transcription 1 (STAT1) and STAT4, thereby blocking
the inﬂammation mediated by STAT-associated signalling
cascades. These ﬁndings suggest that TTAGGG multimers
may ﬁnd broad use in the treatment of diseases characterized
by over-exuberant/persistent immune activation. [121].
Intravenous immunoglobulin (IVIgs) therapy has been
also used for the treatment of SLE. Various mechanisms of
IVIgs have been shown to play a role in the modulation
of SLE: IVIgs suppresses the expansion of autoreactive
B lymphocytes through signalling the FcγRIIB, idiotype-
mediated inhibition of B cell receptors and neutralisation of
cytokines such as the B cell survival factors (B cell activation
factor—B cell activating factor belonging to the TNF family
(BLyS)andAproliferation-inducingligand(APRIL)-)[122].
In case reports and in open trials, high-dose IVIgs (2g/Kg
over a 5-day period) has consistently been shown to be
a beneﬁcial and safe adjunct therapeutic agent for over
20 manifestations in patients with SLE [123]. The use of
IVIgs seems to be particularly successful in those patients
with active disease and concomitant sepsis [MJ Cuadrado,
personal communication].
Statins may also play an important role in the treatment
of SLE patients regarding the prevention of cardiovascular
disease as well as the immunomodulation over the chronic
inﬂammatory activity of the disease. The pleiotropic proper-
ties of statins, in addition to their eﬀects on the suppression
of cholesterol synthesis, include direct inﬂuence on endothe-
lium, plaque formation and thromboxan synthesis as well as
direct and indirect immunomodulatory activities.
Statins have further demonstrated their antithrombotic/
antiinﬂamatory eﬀects on APS patients. In a preliminary
study, our group evaluated the eﬀects of Fluvastatin tre-
atment on monocyte expression and regulation of the
main proteins involved in the characteristic procoagu-
lant/proinﬂammatory state of APS patients [124]. Twenty
patients with APS and previous history of thrombosis
received Fluvastatin (20mg/day) for one month. After
one month of Fluvastatin treatment, monocytes from APS
patients showed a signiﬁcant inhibition of TF, protease-
activated receptors (PAR)-1 and PAR-2, VEGF and Flt1
expression. Proteomic analysis showed signiﬁcant changes
in the protein patterns of monocytes from APS after
Fluvastatin administration, particularly on proteins involved
in thrombotic development: inhibiting Annexin II and
RhoA expression and increasing that of Protein Disulphide
Isomerase. The data of this study supported that Fluvastatin
have multiple profound eﬀects in monocyte activity, which
aredirectlyrelatedtothrombosispreventioninAPSpatients.
Ar e c e n ts t u d yb yF e r r e i r ae ta l .[ 125]d e m o n s t r a t e da
surprisingly reduction of SLE activity measured by SLEDAI
scale after atorvastatin therapy in addition to the improve-
ment of the endothelial-dependent vasodilatation in SLE
patients after a 8 weeks controlled trial. In support for this
observation, Kotyla et al. [126] observed similar reduction of
SLEDAI in the group of female patients treated with another
statin: simvastatin. Reduction of SLEDAI was accompanied
byaprominentsuppressionofTNFαconcentrationinseraof
patients treated. That phenomenon was observed just after 4
weeks of treatment with simvastatin at a dose of 20mg. They
also reported improvement of endothelial function, leading
to the thesis that restoration of endothelial function was not
restricted to the single compound (atorvastatin) but may be
recognized as a class of drug eﬀect. Since TNFα is believed
to mediate endothelial damage, that authors also speculated
that suppression of TNFα levels after statin therapy might be
onemechanismviawhichrestorationofendothelialfunction
occurs.
Because contradictory results were obtained in NZB/W
mice that were given atorvastatin, either orally or intraperi-
toneally [84], and no signiﬁcant eﬀects of ﬂuvastatin on
cardiac events in renal transplant recipients with SLE has
been observed in a very recent study [127], the preliminary
positive ﬁndings must be conﬁrmed by multicentre and
long-term studies to deﬁne whether statin treatment in SLE
patients is indeed associated with a relevant reduction of
cardiovascular morbidity and mortality as well as with an
amelioration of the inﬂammatory status and if this drug
category should be broadly indicated for SLE patients.
In sum, cytokines identiﬁed as major players in the path
physiology of SLE, which have been selected as targets for the
developmentofnoveltherapies(includingIFNs,TNForTh1
cytokines), have also proved to inﬂuence the development
of AT and CVD in that autoimmune disease. Therefore,
therapies directed to reduce or eliminate their expression
would give a double beneﬁt for SLE patients: the control of
thedisease,andthepreventionofATandCVDdevelopment.
6. Conclusions
In spite of the signiﬁcant and continuous advances per-
formed in the discovery of the cellular and molecular mech-
anisms responsible for SLE-related AT, relevant questions
remain still unanswered: what are the direct links between
chronic inﬂammation and the initiation and progression of
vascular stiﬀening and AT? What are the safest and most
eﬀective pharmacologic approaches to limit inﬂammation
even in the absence of disease-related activity?
Cytokine upregulation constitute a major mechanism
that links increased atheroma formation in patients with
SLE. However, because of the cytokines’ function overlap,
their redundant activity, and their synergistic or antagonistic
activity, (which may depend on the cell type, the local
environment, the presence of synergistic or competing
factors, and tissue responsiveness to each cytokine), their
pathophysiological role may be diﬃcult to assess.
Aplethoraofnewtreatmentapproachesusingantibodies
or small molecule inhibitors speciﬁcally targeting cytokines,
cellular receptors, or signalling mechanisms has emerged in
recent years. All of them have shown limited eﬀectiveness,
and, in a similar way to what happened with the “traditional
treatments” administered to SLE patients, showed a number
of adverse eﬀects. Nevertheless, the knowledge continuesJournal of Biomedicine and Biotechnology 9
increasing, and there are two lessons to learn from the
experience to date: (1) that no single treatment is eﬀective
and safe enough; and (2) that every single patient shows
a cellular and molecular proﬁle that physicians should
seriously take into consideration.
Anti-inﬂammatory therapeutic strategies in the setting
of SLE-related AT need to consider a network of interactive
cytokines rather than individual proinﬂammatory factors
in isolation. Genetic proﬁles may also be relevant to the
severity of the disease and the response to each speciﬁc
drug. Probably the best therapeutic strategy would imply a
combination of immunosuppressant and antiinﬂammatory
drugs, which should further be administered taking into
account the cellular and molecular proﬁle speciﬁc of each
SLE patient.
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